LENZ Therapeutics Reports Q3 2026 Results, Reorganization and CEO Succession
VIZZ sales rose 50% quarter over quarter. The company is prioritizing consumer marketing in a strategic reorganization and announced a CEO succession.
Story updates
08:34:30 PM UTC
SquawkNews
LENZ reported Q3 2026 net product sales of $2.6M, a net loss of $31.0M, and plans a reorganization to prioritize consumer marketing and cut projected 2027 operating expenses by over 50%. CEO Eef Schimmelpennink will step down Dec. 1, with CFO Dan Chevallard as interim CEO.Material DetailsContext by…
08:39:58 PM UTC
SquawkNews
LENZ Therapeutics Q3 VIZZ sales jump 50% sequentially on strong demand
Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increasesStrategic reorganization to prioritize consumer marketing, support the continued market expansion of VIZZ and reduce projected 2027 a…